Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Macerich Company (The) Common Stock (MAC) vs Merck & Co., Inc. (MRK) Price & Performance

Macerich Company (The) Common StockTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Macerich Company (The) Common Stock vs Merck & Co., Inc. — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B), while Merck & Co., Inc. trades at $150.03 (market cap $363.59B). The key difference: Merck & Co., Inc. is far larger — about 57.8× Macerich Company (The) Common Stock's market cap, and Macerich Company (The) Common Stock pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.

MACMRK
Market Cap
$6.29B$363.59B
Volume
3,158,1428,036,558
Sector
Real EstateHealth
52-Week High
$26.51$156.43
52-Week Low
$16.20$82.49
Typical Hold Time
0 Days98 Days
Enterprise Value
$10.97B$410.35B
Dividend Yield
3.07%2.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Macerich Company (The) Common Stock

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.

The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MAC
100% Buy0% Sell
Avg holding period · 0 Days
MRK
57% Buy43% Sell
Avg holding period · 98 Days

Top news

Latest headlines on both assets

About Macerich Company (The) Common Stock

The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.

Read more on MAC →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK →